Life sciences company focusing on developing next generation psychedelics medicines to treat unmet needs within mental health space BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) announced having submitted a patent application for new compositions of 2-bromo-LSD it used in treatments of cluster headaches and a wider range of other mental conditions like anxiety, depression and post-traumatic stress disorder (PTSD).
The company is developing new compositions of 2-bromo-LSD going by the title ‘TD-0148A’ which is covered by the new provision patent application.
According to the patent application, TD-0148A is a second-generation lysergic acid diethylamide (LSD) derivative molecule which does not contain hallucinations hence it’s not subject to the regulations of controlled substances.
The company’s chief executive officer, Ahmad Doroudian, says this patent application will help them propel their journey of becoming a market leader in the psychedelics drug space.
“The inventions covered by this provisional patent filing hold great promise, and helps us advance on our path to becoming a leader in the psychedelic drug space which is estimated to become a US$6.85-billion industry by 2027. We are excited to be developing and bringing to market treatments addressing cluster headaches, neuropathic pain and range of mental health conditions, including depression, anxiety and PTSD, and related disorders,” said the CEO.
